Edison. Executive Interview – Erytech Pharma

Posted By :

Erytech is a French oncology company with a red blood cell encapsulation technology. Lead product Graspa has successfully completed a Phase III acute lymphoblastic leukaemia trial and a Phase IIb in acute myeloid leukaemia is ongoing, in addition to a Phase II in pancreatic cancer.

In this interview CEO Gil Beyen explains how Graspa works, its benefits and its other potential applications. He also sets out the company’s plans for the money raised in October 2014 and what investors should look out for in the coming months.


Leave a Reply

Your email address will not be published. Required fields are marked *